2 results
Approved WMORecruiting
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…
Approved WMORecruiting
The aim of our study is to compare one-year outcomes in terms of major adverse cardiovascular events (all cause death, reinfarction, any revascularization and stroke) of 2 different strategies in patients with non-STEMI and multivessel coronary…